While the preclinical data regarding furmonertinib inhibition of EGFR mutants (including T790M and ex20ins) have yet to be released by the manufacturer, recent studies have demonstrated that it is superior to gefitinib in terms of efficacy as a first-line treatment in patients with EGFR mutation-positive locally advanced or metastatic NSCLC [27], in lung adenocarcinoma patients harboring EGFRex20ins with favorable response to furmonertinib as a single agent [28,29], and in combination with anlotinib [30]. Here, EGFR is linked to lung adenocarcinoma.